Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

1.6K
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
1.6K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

2.0K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.0K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

3.0K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
3.0K
Upper Respiratory Drugs: Decongestants01:27

Upper Respiratory Drugs: Decongestants

1.1K
Decongestants are a class of medications used primarily to alleviate nasal congestion, a common symptom resulting from allergies, colds, sinusitis, and other upper respiratory tract infections. These drugs work by activating α-adrenergic receptors, constricting small blood vessels in the nasal membranes. This action results in the opening of clogged nasal passages, thereby facilitating sinus drainage and relieving congestion.
Most decongestants are readily available over-the-counter in...
1.1K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

4.0K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
4.0K
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

1.8K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial.

Addiction (Abingdon, England)·1998
Same author

Addiction medicine.

JAMA·1996
Same author

A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence.

Archives of general psychiatry·1996
Same author

Abuse of flunitrazepam (Rohypnol) and other benzodiazepines in Austin and south Texas.

Journal of psychoactive drugs·1996
Same author

Urine toxicology as an outcome measure in drug abuse clinical trials: must every sample be analyzed?

Journal of addictive diseases·1996
Same author

Buprenorphine as a pharmacotherapy for cocaine abuse: a review of the evidence.

Journal of addictive diseases·1995
Same journal

Opioid use disorder and hospital readmission in the United States from 2010 to 2022: Primary reasons and the complex interplay of comorbid conditions.

Drug and alcohol dependence·2026
Same journal

Impact of medicaid waivers on medication for opioid use disorders in residential facilities: Evidence from twenty-five states.

Drug and alcohol dependence·2026
Same journal

Mental and somatic multimorbidity among individuals with alcohol use disorder: A sex-stratified registry study.

Drug and alcohol dependence·2026
Same journal

Monitoring novel psychoactive substance trends on social media: Analysis of discussions and dashboard implementation.

Drug and alcohol dependence·2026
Same journal

A meta-analysis on the relationship between cultural identity and substance use among indigenous youth.

Drug and alcohol dependence·2026
Same journal

Examining heterogeneity in pathways between alcohol-related factors and drinking during topiramate pharmacotherapy: A person-specific analysis.

Drug and alcohol dependence·2026
See all related articles

Related Experiment Video

Updated: Feb 26, 2026

Preparation of Enantiopure Non-Activated Aziridines and Synthesis of Biemamide B, D, and epiallo-Isomuscarine
11:04

Preparation of Enantiopure Non-Activated Aziridines and Synthesis of Biemamide B, D, and epiallo-Isomuscarine

Published on: June 13, 2022

3.5K

Propylhexdrine.

D R Wesson

    Drug and Alcohol Dependence
    |June 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Propylhexedrine, a nasal decongestant, is under review by the World Health Organization (WHO). While safe for nasal use, oral or injected abuse has been reported, though its abuse potential is low compared to other stimulants.

    More Related Videos

    A Convenient Method for Extraction and Analysis with High-Pressure Liquid Chromatography of Catecholamine Neurotransmitters and Their Metabolites
    13:35

    A Convenient Method for Extraction and Analysis with High-Pressure Liquid Chromatography of Catecholamine Neurotransmitters and Their Metabolites

    Published on: March 1, 2018

    15.4K
    Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones
    06:06

    Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones

    Published on: February 5, 2018

    26.9K

    Related Experiment Videos

    Last Updated: Feb 26, 2026

    Preparation of Enantiopure Non-Activated Aziridines and Synthesis of Biemamide B, D, and epiallo-Isomuscarine
    11:04

    Preparation of Enantiopure Non-Activated Aziridines and Synthesis of Biemamide B, D, and epiallo-Isomuscarine

    Published on: June 13, 2022

    3.5K
    A Convenient Method for Extraction and Analysis with High-Pressure Liquid Chromatography of Catecholamine Neurotransmitters and Their Metabolites
    13:35

    A Convenient Method for Extraction and Analysis with High-Pressure Liquid Chromatography of Catecholamine Neurotransmitters and Their Metabolites

    Published on: March 1, 2018

    15.4K
    Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones
    06:06

    Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones

    Published on: February 5, 2018

    26.9K

    Area of Science:

    • Pharmacology
    • Toxicology
    • Medicinal Chemistry

    Background:

    • Propylhexedrine is a sympathomimetic amine with medicinal applications.
    • The World Health Organization (WHO) is reviewing propylhexedrine for scheduling under the Convention on Psychotropic Substances.
    • This review focuses on the pharmacology, medicinal uses, toxicity, and abuse potential of propylhexedrine.

    Purpose of the Study:

    • To comprehensively review the pharmacology, medicinal uses, toxicity, and abuse potential of propylhexedrine.
    • To provide an evidence base for the WHO Expert Committee's scheduling decision.
    • To specifically emphasize the toxicity and abuse potential of propylhexedrine.

    Main Methods:

    • Literature review of existing studies on propylhexedrine.
    • Analysis of pharmacological data, including mechanism of action and effects.
    • Evaluation of reported medicinal uses, toxicity data, and cases of abuse.

    Main Results:

    • Propylhexedrine is primarily used for temporary nasal decongestion, reducing airway resistance without rebound congestion.
    • Abuse of propylhexedrine nasal inhalers occurs through oral ingestion or intravenous injection, not nasal inhalation.
    • Propylhexedrine exhibits low abuse potential and low preference among stimulant abusers compared to amphetamine, methylphenidate, and phenmetrazine.

    Conclusions:

    • Propylhexedrine is an effective nasal decongestant with a low risk of abuse when used as directed.
    • The primary risks associated with propylhexedrine involve non-intended routes of administration (oral, intravenous).
    • The findings support a nuanced assessment of propylhexedrine's regulatory status, considering both therapeutic use and abuse potential.